NewCardio, a cardiac diagnostic technology provider, has reported that the Heart Rhythm Society (HRS) has accepted an abstract detailing the performance of its patented CardioBip technology for remote wireless monitoring and detection of atrial fibrillation (AF).
The abstract, titled ‘Three-dimensional Atrial Signal Reconstruction Facilitates Remote Detection Of Atrial Fibrillation,’ highlights a new AF detection algorithm based on NewCardio’s 3-D ECG processing platform.
CardioBip is a hand-held device that provides a solution for ECG remote monitoring. Patients can carry the CardioBip with them and use it to generate and transmit synthesized, accurate 12-lead ECGs at physician prescribed intervals of time, during ordinary daily activity or when symptoms develop.
CardioBip works without any cables, cumbersome leads, wires or inconvenient skin electrodes, as the device’s electrodes are integrated, offering potential compatibility with popular hand-held PDA platforms.
Reportedly, on January 12, 2010, the US Patent and Trademark Office had issued patent 7,647,093, titled ‘Apparatus and method for cordless recording and telecommunication transmission of three special ECG leads and their processing.’ This represents the core patent for CardioBip.
Alexei Shvilkin, MD of Beth Israel Deaconess Medical Center and Harvard Medical School, the abstract’s first author and principal investigator, said: “In this study, we showed that NewCardio’s CardioBip-based wireless technology enables the assessment of atrial activity by using ensemble signal processing, 12-lead ECG reconstruction, and 3-D processing of atrial activity.
“The new algorithm detects the difference in atrial activity between AF and sinus rhythm and does not rely on heart rate variability measurements. It has the potential to improve patient monitoring outcomes by differentiating AF from other confounding arrhythmia (like atrial flutter, atrial tachycardia) that may occur after AF ablation.”